ABT heads into its July 15 Q2 print with a fresh analyst initiation, options traders at their least defensive posture in twelve months, and a stock that gave back 2.1% on Tuesday to close at $90.74 — still well below the $115–116 range where insiders were selling in March.
The clearest new development this week is from the Street. Baird initiated coverage on July 1 with an Outperform rating and a $121 target, adding to a consensus that was already firmly constructive: 17 buy-equivalent ratings, a mean target near $116.72, implying roughly 29% upside from current levels. Piper Sandler reiterated Overweight at $115 last week. The direction of travel since April has been a mix of target cuts and rating holds — BofA trimmed to $120 from $150, Piper Sandler dropped to $115 from $135, several others made similar adjustments after the Q1 miss — but no one has downgraded. Bulls point to the Exact Sciences acquisition, a FY26 comparable growth outlook of 6.5–7.5%, and a track record of accretive M&A. Bears flag softness in Nutritional Products and potential intellectual property headwinds. The mean target clustered around $115–121 against a stock at $90 suggests the Street is waiting for earnings to close the gap rather than chasing it higher.
Options positioning backs up that relatively calm tone. The put/call ratio is running near its 52-week low at 0.67, fractionally below its 20-day average and close to the lowest defensive reading of the past year at 0.6666. That puts the z-score near -0.87 — options buyers are not loading up on downside protection ahead of the print. For context, the 52-week high on the PCR was 1.30, so the current setup is closer to complacency than caution. Short interest reinforces this picture: at roughly 1.3% of free float, it has drifted lower across June and is unambiguously low for a large-cap healthcare name. Borrow availability is essentially unlimited, and cost to borrow has ticked up about 32% over the week but remains negligible at 0.35% — there is no short-side pressure building.
The insider signal established in the prior note remains the most structurally interesting feature of the setup. Net insider buying over the past 90 days runs to roughly $1.35 million across multiple open-market purchases — the CFO at $91.50, an independent director at $92.65 for nearly $927k, and a director at $86.82 — all materially below the $115–116 at which executives were selling in March. That cluster of purchases near current levels has not been reversed. The one insider trade this week was a small General Counsel sell of 560 shares at $94.12 on June 26, worth roughly $53k — routine compared with the April-May buying.
The sector backdrop adds some texture. SYK fell 4.7% on Tuesday and ZBH dropped 5.6%, while MDT lost 3.3% on the day. ABT's 2.1% decline looks contained by comparison. On the week, ABT is marginally positive at +0.2% — peers like INSP (+6.9%) and PODD (+5.8%) outperformed, but the broader cohort was mixed. The ORTEX short score sits at 29.1 — low, stable, and consistent with a name where short sellers have been steadily reducing rather than building. Factor scores flag dividend yield as a near-top-decile strength (ranked 98th percentile), with short score rank in the 80th percentile.
What to watch next is squarely the July 15 earnings release: with options the calmest they've been all year, insiders on record as buyers at these levels, and the Street anchored well above the current price, the print becomes less about whether growth is intact and more about whether Abbott can give the Street a reason to close the gap between $90 and those $115–131 price targets.
See the live data behind this article on ORTEX.
Open ABT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
